Oncology – Gynecologic

RCT: Pembrolizumab for persistent, recurrent, or metastatic cervical cancer.

26 Sep, 2021 | 21:43h | UTC

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer – New England Journal of Medicine

Commentary: KEYNOTE-826: Pembrolizumab Plus Chemotherapy in Advanced Cervical Cancer – The ASCO Post

 

---

Guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgery.

26 Aug, 2021 | 08:32h | UTC

European Society of Gynaecological Oncology guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgery – International Journal of Gynecological Cancer

Editorial: Standardizing ovarian cancer surgery and peri-operative care: a European Society of Gynecological Oncology (ESGO) consensus statement

 

---

Cohort study: Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers.

20 Aug, 2021 | 08:39h | UTC

Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study – American Journal of Obstetrics and Gynecology

 

Commentary on Twitter

For #BRCA1 mutation carriers, longer duration of oral contraceptive use (>10 yr) is associated with a greater reduction in #OvarianCancer risk, and the protection is long term. https://t.co/HrrutgaYKX

— Anna Chichura, MD (@AnnaChichuraMD) July 3, 2021

 

---

ASCO Resource-Stratified Guideline: Assessment of adult women with ovarian masses and treatment of epithelial ovarian cancer.

8 Aug, 2021 | 23:38h | UTC

Assessment of Adult Women With Ovarian Masses and Treatment of Epithelial Ovarian Cancer: ASCO Resource-Stratified Guideline – JCO Global Oncology

Commentary: ASCO Publishes Resource-Stratified Guideline on Assessment and Treatment of Ovarian Cancer – The ASCO Post

 

---

Review: Hyperthermic intraperitoneal chemotherapy for ovarian and colorectal cancer

7 May, 2021 | 08:23h | UTC

Hyperthermic Intraperitoneal Chemotherapy for Ovarian and Colorectal Cancer: A Review – JAMA Oncology (free for a limited period)

 

---

RCT: No benefit from immune checkpoint inhibitors in newly diagnosed stage III or IV ovarian cancer

25 Apr, 2021 | 20:57h | UTC

Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39) – Journal of Clinical Oncology

Editorial: Immune Checkpoint Inhibitors in Ovarian Cancer: Can We Bridge the Gap Between IMagynation and Reality?

 

---

RCT: Treatments for vulnerable older adult women with ovarian cancer compared

23 Apr, 2021 | 08:15h | UTC

Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A Randomized Clinical Trial – JAMA Oncology (free for a limited period)

Editorial: Vulnerable Older Adults With Ovarian Cancer—Time to Stop Undertreating (free for a limited period)

 

---

RCT: Secondary cytoreduction followed by chemotherapy vs. chemotherapy alone in platinum-sensitive relapsed ovarian cancer

10 Mar, 2021 | 08:18h | UTC

Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

 

Commentary on Twitter

NEW online: SOC-1 trial—Secondary #cytoreduction followed by #chemotherapy versus chemotherapy alone in platinum-sensitive relapsed #ovariancancer #surgery #gyncsm https://t.co/cFq41Ck9EW pic.twitter.com/5gFsIGLBDA

— The Lancet Oncology (@TheLancetOncol) March 9, 2021

 

---

[Abstract Only] Nationwide cohort study in Sweden shows HPV vaccination linked to reduced risk of invasive cervical cancer

1 Oct, 2020 | 08:56h | UTC

HPV Vaccination and the Risk of Invasive Cervical Cancer – New England Journal of Medicine

News Release: HPV vaccine effective against cervical cancer – Karolinska Institutet

 

---